SynthesisSkin appendage disorders2022
Use of Botulinum Toxin for Androgenic Alopecia: A Systematic Review.
Synthesis in Skin appendage disorders, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 26 citations in OpenAlex.
- Efficacy of type A botulinum toxin treatment for androgenetic alopecia using ultrasound combined with trichoscopy.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Trial
- Review
- Advances in Medicalized Hair Loss Solutions: A Review of Current Clinical Practices and Regenerative Medicine-Based Protocols with Focus on Off-Label Injectable Treatments.Journal of clinical medicine · 2026Review
- Alopecia management from a comparative perspective: pharmacological and pharmaceutical insights in humans, dogs, and cats.Frontiers in veterinary science · 2026Review
- Recent Advances in Drug Development for Hair Loss.International journal of molecular sciences · 2025Review
- Botulinum Toxin in the Treatment of Hair and Scalp Disorders: Current Evidence and Clinical Applications.Toxins · 2025Review
- Androgenetic Alopecia: An Update on Pathogenesis and Pharmacological Treatment.Drug design, development and therapy · 2025Review
- Advances in Migraine Treatment: A Comprehensive Clinical Review.Current protein & peptide science · 2025Review
- Clinical and preclinical approach in AGA treatment: a review of current and new therapies in the regenerative field.Stem cell research & therapy · 2024Review
- High-frequency ultrasonography of the scalp: A comparison between androgenetic alopecia and healthy volunteers.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024Article
- Botulinum Toxin A for Hair Loss Treatment: A Systematic Review of Efficacy, Safety, and Future Directions.JPRAS open · 2023Review
- Treatment of Androgenetic Alopecia: Current Guidance and Unmet Needs.Clinical, cosmetic and investigational dermatology · 2023Review
- Off-Label Use of Botulinum Toxin in Dermatology-Current State of the Art.Molecules (Basel, Switzerland) · 2022Review
Corrections and comments
- Erratum issuedErratum.2022
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this systematic review, we summarize the efficacy and safety of intradermal and intramuscular botulinum toxin injections for androgenic alopecia (AGA). Using PubMed, we conducted a literature search up to February 2021 using the following keyword combinations: "botulinum toxin" or "botox" and "androgenetic alopecia," "hair loss," or "alopecia." Five clinical studies met our inclusion criteria: 4 prospective cohorts and 1 randomized clinical trial (RCT). Study durations ranged from 24 to 60 weeks. No studies included control groups or compared botulinum toxin injections against approved treatments. A total of 165 participants were identified - all of whom were males with AGA. Of the 4 studies measuring response rates (i.e., subjects with >0% hair changes), response rates ranged from 75 to 79.1%. Within studies measuring hair count changes from intramuscular injections, changes ranged from 18 to 20.9%. No serious adverse events were reported. Studies on botulinum toxin injections have produced favorable outcomes for AGA subjects. However, results should be interpreted with caution due to the absence of control groups, small numbers of participants, and relatively low Jadad quality scores. Large RCTs are recommended to confirm efficacy and safety, explore the effects of botulinum toxin on females with pattern hair loss, and establish best practices for intradermal and intramuscular injection methodologies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.